Biological compound preservative
By using HQPrez, a biocomplex preservative composed of chitosaccharides, allicin, streptococcin lactate and oligomycin A, the problem of difficult microbial contamination in serum products in the prior art is solved, and high efficiency and environmental protection are achieved The antibacterial effect is suitable for the storage and storage of serum standards.
Patent Information
- Application Number
- CN202410955170.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
Smart Images

Figure CN118901713A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a biological composite preservative using chitosan oligosaccharide, allicin, nisin and oligomycin A as main components. Background Art
[0002] Preservatives play an important role in liquid reagent products by acting on multiple targets such as the cell membrane, cell wall and enzymes of microorganisms, destroying cell division and inhibiting microbial growth and. In the in vitro diagnostic reagent (IVD) industry, preservatives should meet several conditions: effectively inhibit common microorganisms during the preparation, storage and use of the kit; stable physical and chemical properties; low cost and easy to obtain.
[0003] Sodium azide is the most commonly used preservative. It interferes with the energy supply of microorganisms by blocking the electron transfer of the respiratory chain. It is a highly toxic and explosive compound and its use is restricted. Thimerosal has been used as a preservative for more than 60 years. Its metabolites are neurotoxic organic mercury, and its safety issues have attracted much attention. Gentamicin has a broad antibacterial spectrum, is easy to use, and is cheap. It is easy to develop drug resistance, which poses a strict challenge to the manufacturing environment of IVD products. Isothiazolinones are new and highly efficient preservatives with low working concentrations and good stability. They interfere with energy supply by inhibiting multiple targets in the tricarboxylic acid cycle of microorganisms. They have a strong inhibitory effect on bacteria, molds, yeasts and algae, but their overall antibacterial effect and stability are not as good as the former. In the entire life cycle of IVD products (production, storage, transportation, use, and scrapping), the environmental management system (EHS, Environment, Health, Safety) has increasingly higher requirements for the use of preservatives; EHS-unfriendly preservatives will be gradually eliminated; broad-spectrum, high-efficiency, safe, and environmentally friendly are the future development direction of preservatives.
[0004] The preservation, processing and storage of blood samples are one of the most important issues in IVD product manufacturing; standard serum matrix is an important part of the traceability chain of IVD products. Serum, as the supporting matrix of blood cells, is rich in a variety of nutrients required by microorganisms; bacteria, fungi, viruses and mycoplasma are common contaminants in the production process of serum standards. Preservatives are indispensable in the preservation of serum products. Developing EHS-friendly preservatives to cope with high contamination risk trends is the current industry trend. Summary of the invention
[0005] In view of the technical problems and defects existing in the prior art, the present invention provides a biocomposite preservative (hereinafter referred to as HQPrez) using chitosan oligosaccharide, allicin, nisin, and oligomycin A as main components, and realizes synergistic enhancement of antibacterial function through multiple components. The product shows obvious inhibitory effect on common Gram-negative and Gram-positive bacteria and fungi in the separation and preparation process of serum products; the preservative can protect the protein components in serum from degradation by endogenous proteases; the preservative is environmentally friendly, and inhibits the growth of microorganisms that are easily contaminated by serum through multi-pathway and multi-target antibacterial inhibition, and the working principle is completely different from that of conventional preservatives. The fully automatic biochemical detection platform system performs the most types of clinical tests currently, and serum standards are important substances for calibration of biochemical detection systems. HQPrez can be used to preserve a variety of serum standards and meet the calibration conditions.
[0006] Specifically, the present invention provides a biological composite preservative (HQPrez), which is prepared from chitosan oligosaccharide, allicin, nisin and oligomycin A.
[0007] The preferred concentrations (m / V) of the components of the biological composite preservative are chitosan oligosaccharide 10-30%, nisin 0.10-0.30%, allicin 0.1-0.5%, and oligomycin A 0.005-0.02%.
[0008] The more preferred concentrations (m / V) of the components of the biological composite preservative are chitosan oligosaccharide 20%, nisin 0.15%, allicin 0.3%, and oligomycin A 0.01%.
[0009] The present invention also relates to a method for preparing a biological composite preservative, comprising the following steps:
[0010] (1) weighing chitosan oligosaccharide powder and mixing it with NaCl solution, adjusting the pH with HCl solution, and stirring at room temperature until it is fully dissolved;
[0011] (2) Weigh nisin, allicin, and oligomycin A respectively;
[0012] (3) Fully mix the above components, add NaCl solution, prepare the biocomposite preservative concentrate, sterilize and filter, adjust the pH, and dilute it when using.
[0013] The preferred step (1) is to weigh chitosan oligosaccharide powder and mix it with 0.9% (m / V) NaCl solution, adjust the pH to 6.5 with 1M HCl solution, and stir at room temperature for 30 minutes until it is fully dissolved;
[0014] Preferably, step (3) is to fully mix the above components, and add 0.9% (m / V) NaCl solution to prepare a biocomposite preservative concentrate, which contains 20% (m / V) chitosan oligosaccharide, 0.15% (m / V) nisin, 0.3% (m / V) allicin, 0.01% (m / V) oligomycin A, and sterilize and filter with a 0.22um filter membrane, adjust to pH 6.5, and dilute at a ratio of 1:10 when used.
[0015] The present invention also relates to the use of a biological composite preservative in inhibiting the growth of serum-prone bacteria, wherein the serum-prone bacteria are Escherichia coli and Staphylococcus aureus.
[0016] The present invention also relates to the use of a biological composite preservative in inhibiting the growth of serum-prone fungi, wherein the serum-prone fungi are Aspergillus niger and Mucor.
[0017] The invention also relates to the use of a biological composite preservative in inhibiting the degradation of target protein by protease in serum.
[0018] Technical advantages of the present invention:
[0019] a. Complementary antimicrobial spectrum: The types of serum contamination microorganisms are complex and diverse, and each component of HQPrez exhibits antibacterial ability, such as chitosan oligosaccharides focusing on fungal inhibition, allicin and nisin focusing on bacterial inhibition.
[0020] b. Inhibition of biofilm formation: Biofilm is composed of extracellular matrix secreted by bacteria, which is responsible for communication between microorganisms, attracting groups to gather, hindering the contact between preservatives and bacteria, and achieving drug resistance. Serum contamination is accompanied by the formation of microbial biofilms. Allicin and nisin can effectively inhibit the formation of bacterial biofilms.
[0021] c. Sensitization and synergistic antibacterial effect: Nisin is also used as a sensitizer in the present invention to perforate the bacterial cell membrane to enhance the efficacy of other antibacterial components of HQPrez and achieve synergistic antibacterial effect.
[0022] d. Content protection: Proteases in serum can cause spontaneous degradation of content proteins. Allicin can inhibit the activity of cysteine proteases and prevent spontaneous degradation of serum standard proteins.
[0023] e. Physical protection: Allicin is an oily substance. HQPrez forms an oil film on the surface of serum, with two-phase distribution and physical isolation to enhance antibacterial ability.
[0024] f. Energy metabolism inhibition: Oligomycin further enhances its antibacterial ability by interfering with microbial energy metabolism.
[0025] Beneficial effects of the present invention:
[0026] 1. The present invention uses natural antibacterial raw materials (chitosan oligosaccharide, allicin, nisin, oligomycin A) and is an EHS-friendly biological composite preservative.
[0027] 2. The working principle of the present invention is different from the conventional preservatives of existing IVDs, and multiple antibacterial mechanisms are used to improve the antibacterial efficiency.
[0028] 3. Each component in the present invention has been proven to have a certain degree of microbial growth inhibition function, but the antibacterial efficacy after mixing the components is much stronger than the simple superposition of functions, showing a synergistic enhancement of antibacterial efficacy; especially under long-term and harsh microbial exposure conditions, it shows a synergistic enhancement of antibacterial efficacy.
[0029] 4. The product of the present invention exhibits a significant inhibitory effect on common bacteria and fungi in serum separation, preparation and storage.
[0030] 5. The product of the present invention can protect the protein components in IVD serum standards from degradation by endogenous proteases.
[0031] 6. The product of the present invention is compatible with a variety of serum matrix standards and quality control products. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Example 4 of the present invention - HQPrez inhibits E. coli.-LB culture medium diagram;
[0033] Figure 2 Example 4 of the present invention - HQPrez inhibits S. aureus. - LB culture medium diagram;
[0034] Figure 3 Example 4 of the present invention - HQPrez inhibits E. coli. - serum graph;
[0035] Figure 4 Example 4 of the present invention - HQPrez inhibits S. aureus. - Serum graph;
[0036] Figure 5 Example 5 of the present invention - HQPrez inhibits the growth of serum-prone fungi;
[0037] Figure 6 Example 7 of the present invention - HQPrez preservative configuration protects the target protein against degradation. DETAILED DESCRIPTION
[0038] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, but are not used to limit the present invention.
[0039] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. The test methods for which specific experimental conditions are not specified in the following examples are usually carried out under conventional experimental conditions or according to the experimental conditions recommended by the manufacturer. Unless otherwise specified, the reagents and raw materials used in the present invention can be obtained commercially. The chitosan oligosaccharide powder, nisin, allicin and oligomycin A used in the embodiments of the present invention were purchased from Sigma-Aldrich.
[0040] Example 1
[0041] Preparation of preservative (HQPrez)
[0042] 1) Weigh chitosan oligosaccharide powder and mix it with 0.9% (m / V) NaCl solution, adjust the pH to 6.5 with 1M HCl solution, and stir at room temperature for 30 minutes until it is fully dissolved;
[0043] 2) Weigh nisin, allicin, and oligomycin A;
[0044] 3) The above components were fully mixed at room temperature, and 0.9% (m / V) NaCl solution was added to prepare HQPrez concentrate, which contained 20% (m / V) chitosan oligosaccharide, 0.15% (m / V) nisin, 0.3% (m / V) allicin, and 0.01% (m / V) oligomycin A. The mixture was sterilized and filtered through a 0.22 um filter membrane, and the pH was adjusted to 6.5 to obtain HQPrez concentrate. The dilution ratio was 1:10 when used.
[0045] 4) Prepare a preservative containing only chitosan oligosaccharide according to the above concentration, record it as HQPrez-Chito, and dilute it at a ratio of 1:10 when using it.
[0046] 5) Prepare a preservative containing only nisin according to the above concentration, record it as HQPrez-Nisin, and dilute it at a ratio of 1:10 when using it.
[0047] 6) Prepare a preservative containing only allicin according to the above concentration, record it as HQPrez-Allicin, and dilute it at a ratio of 1:10 when used.
[0048] 7) Prepare a preservative containing only oligomycin according to the above concentration, record it as HQPrez-OligoA, and dilute it at a ratio of 1:10 when using it.
[0049] Example 2
[0050] Preparation of preservative (HQPrez)
[0051] 1) Weigh the oligosaccharide powder and mix it with 0.9% (m / V) NaCl solution, adjust the pH to 6.5 with 1M HCl solution, and stir at room temperature for 30 minutes until it is fully dissolved;
[0052] 2) Weigh nisin, allicin, and oligomycin A;
[0053] 3) The above components were fully mixed at room temperature, and 0.9% (m / V) NaCl solution was added to prepare HQPrez concentrate, which contained 10% (m / V) chitosan oligosaccharide, 0.3% (m / V) nisin, 0.5% (m / V) allicin, 0.005% (m / V) oligomycin A, and sterilized and filtered through a 0.22 um filter membrane, and adjusted to pH 6.5 to obtain HQPrez concentrate. The dilution ratio was 1:10 when used.
[0054] 4) Prepare a preservative containing only chitosan oligosaccharide according to the above concentration, record it as HQPrez-Chito, and dilute it at a ratio of 1:10 when using it.
[0055] 5) Prepare a preservative containing only nisin according to the above concentration, record it as HQPrez-Nisin, and dilute it at a ratio of 1:10 when using it.
[0056] 6) Prepare a preservative containing only allicin according to the above concentration, record it as HQPrez-Allicin, and dilute it at a ratio of 1:10 when used.
[0057] 7) Prepare a preservative containing only oligomycin according to the above concentration, record it as HQPrez-OligoA, and dilute it at a ratio of 1:10 when using it.
[0058] Example 3
[0059] Preparation of preservative (HQPrez)
[0060] 1) Weigh the oligosaccharide powder and mix it with 0.9% (m / V) NaCl solution, adjust the pH to 6.5 with 1M HCl solution, and stir at room temperature for 30 minutes until it is fully dissolved;
[0061] 2) Weigh nisin, allicin, and oligomycin A;
[0062] 3) The above components were fully mixed at room temperature, and 0.9% (m / V) NaCl solution was added to prepare HQPrez concentrate, which contained 30% (m / V) chitosan oligosaccharide, 0.1% (m / V) nisin, 0.1% (m / V) allicin, 0.02% (m / V) oligomycin A, and sterilized and filtered through a 0.22 um filter membrane, and adjusted to pH 6.5 to obtain HQPrez concentrate. The dilution ratio was 1:10 when used.
[0063] 4) Prepare a preservative containing only chitosan oligosaccharide according to the above concentration, record it as HQPrez-Chito, and dilute it at a ratio of 1:10 when using it.
[0064] 5) Prepare a preservative containing only nisin according to the above concentration, record it as HQPrez-Nisin, and dilute it at a ratio of 1:10 when using it.
[0065] 6) Prepare a preservative containing only allicin according to the above concentration, record it as HQPrez-Allicin, and dilute it at a ratio of 1:10 when used.
[0066] 7) Prepare a preservative containing only oligomycin according to the above concentration, record it as HQPrez-OligoA, and dilute it at a ratio of 1:10 when using it.
[0067] Example 4
[0068] Example 1 Inhibition of the growth of different types of serum-susceptible bacteria by the HQPrez preservative prepared
[0069] 1) Activation of strains: The preserved strains, Escherichia coli and Staphtlococcus aureus, were inoculated into 100 ml LB liquid culture medium (Jiuding Chemical) at 37° C. and cultured in a shaking incubator at 250 rpm for 24 hours until the logarithmic growth phase.
[0070] 2) Bacterial growth inhibition test: The growth inhibition of HQPrez prepared in Example 1 on different bacteria was determined using a growth inhibition method. Cells in the logarithmic growth phase were inoculated in a 24-well plate at 5*105 cells / well, HQPrez was added to the bacterial culture medium, and cultured at 37°C, 250 rpm in a shaking incubator. OD600 was measured every 2 hours to establish a growth curve; a 10-fold diluted penicillin-streptomycin mixture (Solarbio) was used as a positive control, and ultrapure water was used as a negative control.
[0071] 3) Mix LB liquid medium and serum (prepared in our laboratory according to conventional methods) at a ratio of 1:1 (V / V) to prepare serum medium.
[0072] 4) Following the same steps as above, test the growth inhibition of bacteria by HQPrez in the presence of serum; the statistical results are shown in Figure 1-Figure 4 Escherichia coli (Gram-negative bacteria G-) and Staphylococcus aureus (Gram-positive bacteria G+) are the most common microbial groups in serum treatment. Figure 1It shows that when E. coli is cultured in LB medium, the microorganisms show typical logarithmic growth characteristics, penicillin-streptomycin shows strong inhibition on the microorganisms, and the bacteria hardly proliferate, and HQPrez shows an effect similar to penicillin-streptomycin dual antibody; Figure 2 It was shown that penicillin-streptomycin and HQPrez showed considerable inhibitory effects on Staphylococcus aureus cultured in LB medium; Figure 3 HQPrez was shown to inhibit the growth of E. coli in serum; Figure 4 HQPrez was shown to inhibit the growth of Staphylococcus aureus in serum.
[0073] Example 5
[0074] Example 1 Inhibition of the growth of different types of serum-susceptible fungi by the HQPrez preservative prepared
[0075] 1) Activation of strains: Preserved Aspergillus niger and Mucor racemosus were inoculated into 100 ml of sterile Czapek broth (Zeye Biotech) and cultured at 28° C. and 250 rpm for 72 hr until the logarithmic growth phase.
[0076] 2) Take 200 ml of solid Czapek medium (Sigma-Aldrich) and sterilize at 121°C for 30 min. When the temperature reaches 42°C, take 14 ml of the medium and 1 ml of the bacterial solution under sterile conditions, mix thoroughly, and pour on a plate.
[0077] 3) Determine the antibacterial ability using the agar diffusion method: After the plate solidifies, use a 5 mm sterile punch to punch holes in the agar.
[0078] 4) 500ul of different antimicrobial samples were placed in the agar wells, sterile water was used as the negative control, 100x amphotericin B (Invitrogen) was used as the positive control, and Czapek broth was used as the blank control.
[0079] 5) Place the plate in a refrigerator for 3 hours to allow the sample to fully diffuse into the agar layer.
[0080] 6) Incubate at 28°C for 48 hours, measure the diameter of the inhibition zone, and repeat the test three times for each sample to obtain the average value. 7) Calculate the antibacterial efficiency according to the following formula: Inhibition rate (%) = [(diameter of the sample inhibition zone - diameter of the inhibition zone of Czapek's medium)] / [(diameter of the inhibition zone of amphotericin - diameter of the inhibition zone of Czapek's medium)] x 100%, and test the growth inhibition of easily contaminated fungi by HQPrez serum; the statistical results are shown in Figure 5, HQPrez showed growth inhibition against Aspergillus niger and Mucor. Sterile water was used as negative control and amphotericin as positive control; within 48 hours, amphotericin showed strong inhibition against both molds; HQPrez showed slightly stronger inhibition against Mucor than Aspergillus niger. Sterile water showed partial growth inhibition, which may be due to the diffusion of water in the wells, resulting in a decrease in nutrients in the culture medium that was insufficient to support bacterial growth.
[0081] Example 6
[0082] Example 1: Test of the stability of HQPrez prepared in Example 1 on serum substances and the long-term antibacterial synergistic enhancement of each component
[0083] 1) The most stringent preservation and stability test for raw materials of serum diagnostic reagents is the opening stability test. Taking the CRP test kit as an example, "the reagent should be kept away from light after opening the bottle and can be stable for 28 days at 2℃~8℃". According to this principle, the opening stability test is carried out.
[0084] 2) Take frozen whole sheep blood raw material (Beijing Yukunrongda Trading), thaw it in a 4°C cold storage, filter it with four or eight layers of gauze, pour it into a stainless steel bucket, and discard obvious turbidity; coarsely filter the whole sheep blood with a 0.45μm filter membrane.
[0085] 3) Collect sheep serum by filtering sequentially through a 0.45 μm filter membrane (Millipore) and a 0.20 μm filter membrane (Millipore).
[0086] 4) Accurately measure a certain amount of serum and add HQPrez-Chito, HQPrez-Nisin, HQPrez-Allicin, HQPrez-OligoA and HQPrez respectively.
[0087] 5) The serum containing different preservative ingredients was opened and stored in a refrigerator at 2°C to 8°C, and the morphology of the serum was observed every day.
[0088] 6) Set up control groups containing sodium azide and distilled water respectively; the statistical results are shown in Table 1.
[0089] Table 1 The long-term antiseptic and antibacterial effects of each component of HQPrez were determined by the serum material opening bottle exposure test. The serum material opening bottle test is the most stringent antiseptic test. By exposing the serum material to the storage environment, the microbial contamination is continuously observed. Each component can show a certain microbial growth inhibition effect at the beginning of storage, but after 5 days, visible microbial contamination occurs to varying degrees. The full-component HQPrez shows an antibacterial effect similar to that of sodium azide; the antibacterial effect of HQPrez occurs within the entire experimental period of 28 days and can be extended to 35-36 days (data not shown), indicating that the growth inhibition effect of microorganisms after the mixture of chitosan, allicin, lactobacillus, and oligomycin is much stronger than the superposition of the effects of single components, achieving synergistically enhanced antibacterial efficacy, especially for the long-term storage of serum products, HQPrez achieves a significant degree of synergistic enhancement of microbial growth inhibition.
[0090] Table 1
[0091]
[0092] Example 7
[0093] Protection of HQPrez preservative prepared in Example 1 on serum quality control standard
[0094] 1) Take frozen sheep whole blood raw materials (Beijing Yukunrongda Trading), thaw them in a 4°C cold storage, filter them with four or eight layers of gauze, pour them into a stainless steel bucket, and discard obvious turbidity; coarsely filter the sheep whole blood with a 0.45μm filter membrane.
[0095] 2) Collect sheep serum by filtering sequentially through a 0.45 μm filter membrane (Millipore) and a 0.20 μm filter membrane (Millipore).
[0096] 3) Accurately measure 300 ml of serum, add 0.00048 g of human glycosylated hemoglobin (HBA1C, Shenzhen Feipeng) and 0.300 g of sodium azide (Seebio) in sequence, stir with a magnetic stirrer for 2 hours, and mix thoroughly.
[0097] 4) Take a sample from the mixed solution, measure the concentration of glycated hemoglobin therein using a fully automatic biochemical analyzer (Hitachi 7180) and the "Glycated Hemoglobin Assay Kit - Latex Immunoturbidimetry" (Sino-Biotech), and conduct semi-finished product inspection: calculate the relative deviation between the measured value and the preset value of the formula. If the relative deviation exceeds ±10%, the addition amount needs to be readjusted until the relative deviation does not exceed ±10%.
[0098] 5) Add 5% sucrose. Stir thoroughly for about 2 hours. Filter again with 0.45μm+0.20μm, collect the filtrate, obtain the glycated hemoglobin control product, and dilute it in multiples to obtain 4 concentrations of quality control standards. 6) Accurately measure 260ml of serum, add 0.00048g of human glycated hemoglobin (HBA1C, Shenzhen Feipeng), 30ml of HQPrez concentrate, and then use filtered sheep serum to make up to 300ml, stir for 2hr to mix.
[0099] 7) Samples were collected and stored at -20°C, 4°C, 20°C, 37°C, and 65°C, and the glycated hemoglobin concentration was measured using an automatic biochemical analyzer after 48 hours. The statistical results are shown in Figure 6 As the storage temperature increases, endogenous proteases in serum will non-specifically hydrolyze the content proteins, causing the concentration to decrease. Since this degradation does not occur in the case of microbial contamination, it is known that the sodium azide preservative system does not have the ability to inhibit non-specific hydrolysis by proteases.
[0100] Example 8
[0101] Test on the anti-interference and stability of HQPrez preservative prepared in Example 1 on serum markers
[0102] 1) Calibration of commercial test kit: The commercial test kit "Glycated Hemoglobin Assay Kit - Latex Immunoturbidimetry" (Sino-Biotech) was calibrated using a fully automatic biochemical analyzer (Hitachi 7180) using a glycated hemoglobin calibrator containing HQPrez.
[0103] 2) Calibration accuracy determination: The calibrated kit was used to measure the "Glycated Hemoglobin Calibrator" (Sino-Biotech) in the commercial kit. The determination was repeated 3 times, and the average of the determination results was calculated. The calibration results were analyzed to see whether they were within the reference value ±15% range. The experimental results are shown in Table 2. The relative deviations of the three batches of glycated hemoglobin calibrators were ≤±15%, which met the industry standards. The "Glycated Hemoglobin Calibrator" provided by the commercial kit "Glycated Hemoglobin Assay Kit-Latex Immunoturbidimetry" (Sino-Biotech) uses a sodium azide preservative system. This experiment shows that the HQPrez system is comparable to the sodium azide preservative system in the glycated hemoglobin serum calibrator.
[0104] Table 2
[0105]
[0106] 3) Traceability determination: The calibrated kit was used to determine the national standard substance for glycated hemoglobin "GBW09181 (Beijing Hospital, Ministry of Health)" for three times, and the average value of the determination results was calculated to analyze whether the test results of the national labeled substances were within the reference value "±15%". The experimental results are shown in Table 3. The relative deviations of the measured glycated hemoglobin national calibrators were ≤±15%, which met the traceability industry standards.
[0107] Table 3
[0108] 4) Determination of inter-bottle difference: Use the above calibrated kit to measure 10 bottles of the same batch of glycated hemoglobin calibrators (including HQPrez) once each, and calculate the measurement mean (1) and standard deviation (s1). Use another bottle of the above 10 bottles to repeat the measurement 10 times, calculate the measurement mean (2) and standard deviation (s2), and calculate the inter-bottle difference according to the following formula to analyze whether the quality control product test results are within the reference value ± 7% "range. The experimental results are shown in Table 4. The inter-bottle difference CV% of the measured glycated hemoglobin calibrators is ≤7%, which meets the industry standards.
[0109] Table 4
[0110]
[0111] 5) Stability test: A stability study was conducted on the HQPrez glycated hemoglobin calibrator. The samples were stored at 2°C to 8°C and tested every 15 days in the first month and every 2 months after 2 months. The stability under normal storage conditions was observed and the test results were analyzed to see if they were within the range of "reference value ±15%" of the quality control product. The experimental results are shown in Table 5. The calibrator had good stability under storage conditions of 2 to 8°C, and the measured values were all within the range of ±15%, meeting industry standards.
[0112] Table 5
[0113]
[0114] Example 9
[0115] Example 1 Protection of HQPrez preservatives on various serum standards
[0116] 1) Fixed value biochemical quality control products are standard reagents for fixing the values of a series of routine biochemical items using a fully automatic biochemical analyzer; the production process is to add a series of standard substances of known concentrations into a human serum matrix (such as the "glycated hemoglobin labeling products" listed in Example 6); there are many commercially available biochemical quality control products, such as "Zhongsheng Beikong-Biochemical Multi-composite Quality Control Products-Beijing Medical Device Registration No. 20162401352" contains 54 substances, corresponding to 54 tests, and "Biochemical Composite Fixed Value Quality Control Products (Guangdong Medical Device Registration No. 20152401097 Shenzhen Mindray Bio-Medical Electronics Co., Ltd., etc."
[0117] 2) According to the content of the "Beijing Medical Device Registration No. 20162401352 Publicity Document", the original sodium azide preservative system was replaced with the HQPrez preservative system, and a biochemical composite quality control product (including HQPrez) was obtained.
[0118] 3) Use HQPrez to calibrate the "biochemical composite quality control product (Sino-Bio"); perform calibration accuracy, traceability, bottle-to-bottle difference, and stability tests, as in Example 8. The statistical results are shown in Table 6. After using the biochemical composite quality control product (HQPrez) to calibrate the Sino-Bio composite biochemical test kit, the detection consistency is good, which is in line with expectations; the Mindray test kit is calibrated according to the same principle, and similar data are obtained (data not shown).
[0119] Table 6
[0120]
[0121]
[0122] Referring to the methods of Examples 4 to 9, the HQPrez prepared in Examples 2 and 3 were tested to obtain results similar to those of the HQPrez prepared in Example 1.
[0123] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A biological composite preservative, characterized in that: The biological composite preservative is prepared from chitosan oligosaccharide, allicin, nisin and oligomycin A.
2. The biocomposite preservative according to claim 1, characterized in that: The concentration (m / V) of each component of the biological composite preservative is chitosan oligosaccharide 10-30%, nisin 0.10-0.30%, allicin 0.1-0.5% and oligomycin A 0.005-0.02%.
3. The biocomposite preservative according to claim 1, characterized in that: The concentration (m / V) of each component of the biological composite preservative is 20% of chitosan oligosaccharide, 0.15% of nisin, 0.3% of allicin and 0.01% of oligomycin A.
4. A method for preparing the biocomposite preservative according to any one of claims 1 to 3, characterized in that: The steps include: (1) weighing chitosan oligosaccharide powder and mixing it with NaCl solution, adjusting the pH with HCl solution, and stirring at room temperature until it is fully dissolved; (2) Weigh nisin, allicin, and oligomycin A respectively; (3) Fully mix the above components, add NaCl solution, prepare the biocomposite preservative concentrate, sterilize and filter, adjust the pH, and dilute it when using.
5. The method for preparing the biocomposite preservative according to claim 4, characterized in that: The step (1) comprises weighing chitosan oligosaccharide powder and mixing it with 0.9% (m / V) NaCl solution, adjusting the pH to 6.5 with 1M HCl solution, and stirring at room temperature for 30 minutes until the mixture is fully dissolved; The step (3) is to fully mix the above components, and add 0.9% (m / V) NaCl solution to prepare a biological composite preservative concentrate, which contains 20% (m / V) chitosan oligosaccharide, 0.15% (m / V) nisin, 0.3% (m / V) allicin, 0.01% (m / V) oligomycin A, and filter through a 0.22 um filter membrane for sterilization, and adjust the pH to 6.
5. The dilution ratio during use is 1:
10.
6. Use of the biological composite preservative according to any one of claims 1 to 3 in inhibiting the growth of bacteria that are prone to contaminating serum.
7. The use according to claim 6, characterized in that: The serum is easily contaminated by bacteria such as Escherichia coli and Staphylococcus aureus.
8. Use of the biological composite preservative according to any one of claims 1 to 3 in inhibiting the growth of serum-prone fungi.
9. The use according to claim 8, characterized in that: The serum is easily contaminated by fungi such as Aspergillus niger and Mucor.
10. Use of the biocomposite preservative according to any one of claims 1 to 3 in inhibiting the degradation of target protein by proteases in serum.
